Camilla Chong

Company: InflaRx Group

Job title: Chief Medical Officer

Seminars:

Complement C5a Drug Development for Immuno-Dermatology Indications 1:45 pm

The role of C5a/C5aR in chronic inflammation has become increasingly clear in recent years, making C5a & C5aR attractive targets for many immune-inflammatory diseases  InflaRx have two potential therapeutics targeting C5a with the anti-C5a antibody (vilobelimab) and an oral anti-C5aR inhibitor (INF-904); with initial focus on immune-dermatology indications such as hidradenitis suppurativa, pyoderma gangrenosum and…Read more

day: Day One Clinical Track PM